FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Regulators Strengthen Global Crackdown on Finfluencers

A new collaborative approach targets financial influencers amid rising concerns.Highlights: Financial regulators unite to control finfluencers' market impact.Concerns...
FinTech

ECB Strengthens Digital Euro Rollout with Standard Setter Agreements

New collaborations aim to facilitate the digital euro's global integration.Highlights: ECB partners with key global standard setters.Agreements aim...
FinTech

CreditNature Strengthens Nature Restoration Funding Through Everyday Transactions

New partnership enables businesses to support environmental initiatives seamlessly.Highlights: CreditNature teams up with Stabiliti for eco-friendly funding.Businesses can...
FinTech

FedNow Strengthens Instant Payments Security with New API Tool

New API tool enhances security for immediate digital transactions in the U.S.Highlights: FedNow introduces a new API tool...